Gadobutrol

DB06703ApprovedInvestigationalSmall moleculeGadolinium-based Contrast Agent

Gadobutrol is a gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume.

Mechanism: In MRI, visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with differences in proton density, the spin-lattice or longitudinal relaxation times (T1), and the spin-spin or transverse relaxation time (T2).
When placed in a magnetic field, gadobutrol shortens the T1 and T2 relaxation times. The extent of decrease of T1 and T2 relaxation times, and therefore the amount of signal enhancement obtained from gadobutrol, is based upon several factors including the concentration of gadobutrol in the tissue, the field strength of the MRI system, and the relative ratio of the longitudinal and transverse relaxation times. At the recommended dose, the T1 shortening effect is observed with the greatest sensitivity in T1-weighted magnetic resonance sequences. In T2*-weighted sequences, the induction of local magnetic field inhomogeneities by the large magnetic moment of gadolinium and at high concentrations (during bolus injection) leads to a signal decrease.
Curator reviewed · 2 references
Primary indication: Gadobutrol is indicated for use with magnetic resonance imaging for the following diagnostic processes: - To detect and visualize areas with disrupted blood-brain barrier and/or abnormal vascularity of the central nervous system in adult and...Curator reviewed · 5 structured indications
Formula / weight: C₁₈H₃₁GdN₄O₉ · 604.72 g/mol (avg)
First approval: Canada, 2007 · United States, 2011
Code names: BAY86-4875 · ZK-135079
Brand names: Gadavist
Gadovist